Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887250 | 1.00 | MLYCD (0.37) | MLYCDTSPOBCL2A1MEN1KMT2A | |
| SCHEMBL12675057 | 0.89 | GRM2 (0.36) | GRM2 | |
| SCHEMBL1266645 | 0.88 | BCL2A1 (0.37) | MLYCDBCL2A1ALDH1A1LMNAGRM2 | |
| SCHEMBL1267786 | 0.86 | ERN1 (0.39) | GRM2 | |
| SCHEMBL1890755 | 0.84 | GRM2 (0.33) | LMNAGRM2 | |
| SCHEMBL2599983 | 0.84 | GRM2 (0.37) | GRM2 | |
| SCHEMBL12675091 | 0.84 | ADORA2B (0.39) | LMNAGRM2 | |
| SCHEMBL12674771 | 0.83 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL1267881 | 0.82 | KCNH2 (0.39) | GRM2 | |
| SCHEMBL2599988 | 0.81 | SLC13A5 (0.36) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | MLYCD 2440/4885TSPO 2685/4885BCL2A1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.